Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021;23:1231–1251.

• PubMed
Louis DN, Perry A, Wesseling P, The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021;23:1231–1251.34185076)| false
• Search Google Scholar
• Export Citation

Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803–820.

• PubMed
Louis DN, Perry A, Reifenberger G, The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803–820.27157931)| false
• Search Google Scholar
• Export Citation

Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–773.

• PubMed
Yan H, Parsons DW, Jin G, IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–773.19228619)| false
• Search Google Scholar
• Export Citation

Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010;75:1560–1566.

• PubMed
Houillier C, Wang X, Kaloshi G, IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010;75:1560–1566.)| false
• Search Google Scholar
• Export Citation

Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372:2481–2498.

• PubMed
Brat DJ, Verhaak RG, Aldape KD, Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372:2481–2498.26061751)| false
• Search Google Scholar
• Export Citation

Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015;372:2499–2508.

• PubMed
Eckel-Passow JE, Lachance DH, Molinaro AM, Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015;372:2499–2508.26061753)| false
• Search Google Scholar
• Export Citation

Gritsch S, Batchelor TT, Gonzalez Castro LN. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer 2022;128:47–58.

• PubMed
Gritsch S, Batchelor TT, Gonzalez Castro LN. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer 2022;128:47–58.34633681)| false
• Search Google Scholar
• Export Citation

Wiestler B, Capper D, Sill M, et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 2014;128:561–571.

• PubMed
Wiestler B, Capper D, Sill M, Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 2014;128:561–571.25008768)| false
• Search Google Scholar
• Export Citation

Weller M, Weber RG, Willscher E, et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 2015;129:679–693.

• PubMed
Weller M, Weber RG, Willscher E, Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 2015;129:679–693.25783747)| false
• Search Google Scholar
• Export Citation

Nitta M, Muragaki Y, Maruyama T, et al. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection. Neurosurg Focus 2015;38:E7.

• PubMed
Nitta M, Muragaki Y, Maruyama T, Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection. Neurosurg Focus 2015;38:E7.25599276)| false
• Search Google Scholar
• Export Citation

Baumert BG, Hegi ME, van den Bent MJ, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 2016;17:1521–1532.

• PubMed
Baumert BG, Hegi ME, van den Bent MJ, Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 2016;17:1521–1532.27686946)| false
• Search Google Scholar
• Export Citation

Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150–4154.

• PubMed
Sanson M, Marie Y, Paris S, Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150–4154.19636000)| false
• Search Google Scholar
• Export Citation

Sahm F, Reuss D, Koelsche C, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 2014;128:551–559.

• PubMed
Sahm F, Reuss D, Koelsche C, Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 2014;128:551–559.)| false
• Search Google Scholar
• Export Citation

Pai T, Epari S, Desai S, et al. Histological spectrum of oligodendroglial tumors: only a subset shows 1p/19q codeletion. Neurol India 2017;65:113–120.

• PubMed
Pai T, Epari S, Desai S, Histological spectrum of oligodendroglial tumors: only a subset shows 1p/19q codeletion. Neurol India 2017;65:113–120.)| false
• Search Google Scholar
• Export Citation

Neumann JE, Dorostkar MM, Korshunov A, et al. Distinct histomorphology in molecular subgroups of glioblastomas in young patients. J Neuropathol Exp Neurol 2016;75:408–414.

• PubMed
Neumann JE, Dorostkar MM, Korshunov A, Distinct histomorphology in molecular subgroups of glioblastomas in young patients. J Neuropathol Exp Neurol 2016;75:408–414.26975364)| false
• Search Google Scholar
• Export Citation

Dubbink HJ, Atmodimedjo PN, Kros JM, et al. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol 2016;18:388–400.

• PubMed
Dubbink HJ, Atmodimedjo PN, Kros JM, Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol 2016;18:388–400.26354927)| false
• Search Google Scholar
• Export Citation

Labussière M, Idbaih A, Wang XW, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 2010;74:1886–1890.

• PubMed
Labussière M, Idbaih A, Wang XW, All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 2010;74:1886–1890.)| false
• Search Google Scholar
• Export Citation

Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol 2013;125:621–636.

• PubMed
Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol 2013;125:621–636.23512379)| false
• Search Google Scholar
• Export Citation

Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 2020;139:603–608.

• PubMed
Brat DJ, Aldape K, Colman H, cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 2020;139:603–608.31996992)| false
• Search Google Scholar
• Export Citation

Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 2018;136:805–810.

• PubMed
Brat DJ, Aldape K, Colman H, cIMPACT-NOW update 3: recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 2018;136:805–810.30259105)| false
• Search Google Scholar
• Export Citation

Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012;3:709–722.

• PubMed
Jiao Y, Killela PJ, Reitman ZJ, Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012;3:709–722.22869205)| false
• Search Google Scholar
• Export Citation

Leeper HE, Caron AA, Decker PA, et al. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget 2015;6:30295–30305.

• PubMed
Leeper HE, Caron AA, Decker PA, IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget 2015;6:30295–30305.26210286)| false
• Search Google Scholar
• Export Citation

Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2015;129:133–146.

• PubMed
Reuss DE, Sahm F, Schrimpf D, ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2015;129:133–146.25427834)| false
• Search Google Scholar
• Export Citation

Arita H, Narita Y, Fukushima S, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 2013;126:267–276.

• PubMed
Arita H, Narita Y, Fukushima S, Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 2013;126:267–276.23764841)| false
• Search Google Scholar
• Export Citation

Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013;110:6021–6026.

• PubMed
Killela PJ, Reitman ZJ, Jiao Y, TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013;110:6021–6026.)| false
• Search Google Scholar
• Export Citation

Appay R, Dehais C, Maurage CA, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol 2019;21:1519–1528.

• PubMed
Appay R, Dehais C, Maurage CA, CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol 2019;21:1519–1528.)| false
• Search Google Scholar
• Export Citation

Cimino PJ, Holland EC. Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas. Neuro Oncol 2019;21:819–821.

• PubMed
Cimino PJ, Holland EC. Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas. Neuro Oncol 2019;21:819–821.30918961)| false
• Search Google Scholar
• Export Citation

Reis GF, Pekmezci M, Hansen HM, et al. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization grades II-III) astrocytomas. J Neuropathol Exp Neurol 2015;74:442–452.

• PubMed
Reis GF, Pekmezci M, Hansen HM, CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization grades II-III) astrocytomas. J Neuropathol Exp Neurol 2015;74:442–452.25853694)| false
• Search Google Scholar
• Export Citation

Yang RR, Shi ZF, Zhang ZY, et al. IDH mutant lower grade (WHO grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Brain Pathol 2020;30:541–553.

• PubMed
Yang RR, Shi ZF, Zhang ZY, IDH mutant lower grade (WHO grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Brain Pathol 2020;30:541–553.31733156)| false
• Search Google Scholar
• Export Citation

Meyronet D, Esteban-Mader M, Bonnet C, et al. Characteristics of H3 K27M-mutant gliomas in adults. Neuro Oncol 2017;19:1127–1134.

• PubMed
Meyronet D, Esteban-Mader M, Bonnet C, Characteristics of H3 K27M-mutant gliomas in adults. Neuro Oncol 2017;19:1127–1134.28201752)| false
• Search Google Scholar
• Export Citation

Kristensen BW, Priesterbach-Ackley LP, Petersen JK, et al. Molecular pathology of tumors of the central nervous system. Ann Oncol 2019;30:1265–1278.

• PubMed
Kristensen BW, Priesterbach-Ackley LP, Petersen JK, Molecular pathology of tumors of the central nervous system. Ann Oncol 2019;30:1265–1278.31124566)| false
• Search Google Scholar
• Export Citation

Schreck KC, Ranjan S, Skorupan N, et al. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol 2019;143:87–93.

• PubMed
Schreck KC, Ranjan S, Skorupan N, Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol 2019;143:87–93.30864101)| false
• Search Google Scholar
• Export Citation

Louis DN, Giannini C, Capper D, et al. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 2018;135:639–642.

• PubMed
Louis DN, Giannini C, Capper D, cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 2018;135:639–642.29497819)| false
• Search Google Scholar
• Export Citation

Buczkowicz P, Hoeman C, Rakopoulos P, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 2014;46:451–456.

• PubMed
Buczkowicz P, Hoeman C, Rakopoulos P, Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 2014;46:451–456.24705254)| false
• Search Google Scholar
• Export Citation

Ryall S, Krishnatry R, Arnoldo A, et al. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Acta Neuropathol Commun 2016;4:93.

• PubMed
Ryall S, Krishnatry R, Arnoldo A, Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Acta Neuropathol Commun 2016;4:93.27577993)| false
• Search Google Scholar
• Export Citation

Ebrahimi A, Skardelly M, Schuhmann MU, et al. High frequency of H3 K27M mutations in adult midline gliomas. J Cancer Res Clin Oncol 2019;145:839–850.

• PubMed
Ebrahimi A, Skardelly M, Schuhmann MU, High frequency of H3 K27M mutations in adult midline gliomas. J Cancer Res Clin Oncol 2019;145:839–850.30610375)| false
• Search Google Scholar
• Export Citation

Mackay A, Burford A, Carvalho D, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 2017;32:520–537.e5.

• PubMed
Mackay A, Burford A, Carvalho D, Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 2017;32:520–537.e5.28966033)| false
• Search Google Scholar
• Export Citation

Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012;22:425–437.

• PubMed
Sturm D, Witt H, Hovestadt V, Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012;22:425–437.23079654)| false
• Search Google Scholar
• Export Citation

Jiang H, Cui Y, Wang J, et al. Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 World Health Organization classification of tumors of the central nervous system. Oncotarget 2017;8:20354–20361.

• PubMed
Jiang H, Cui Y, Wang J, Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 World Health Organization classification of tumors of the central nervous system. Oncotarget 2017;8:20354–20361.27888628)| false
• Search Google Scholar
• Export Citation

Wick W, Roth P, Hartmann C, et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol 2016;18:1529–1537.

• PubMed
Wick W, Roth P, Hartmann C, Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol 2016;18:1529–1537.)| false
• Search Google Scholar
• Export Citation

Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 2014;32:783–790.

• PubMed
Cairncross JG, Wang M, Jenkins RB, Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 2014;32:783–790.24516018)| false
• Search Google Scholar
• Export Citation

Everhard S, Kaloshi G, Crinière E, et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 2006;60:740–743.

• PubMed
Everhard S, Kaloshi G, Crinière E, MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 2006;60:740–743.17192931)| false
• Search Google Scholar
• Export Citation

Gorovets D, Kannan K, Shen R, et al. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res 2012;18:2490–2501.

• PubMed
Gorovets D, Kannan K, Shen R, IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res 2012;18:2490–2501.22415316)| false
• Search Google Scholar
• Export Citation

Wahl M, Phillips JJ, Molinaro AM, et al. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol 2017;19:242–251.

• PubMed
Wahl M, Phillips JJ, Molinaro AM, Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol 2017;19:242–251.)| false
• Search Google Scholar
• Export Citation

Arita H, Yamasaki K, Matsushita Y, et al. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 2016;4:79.

• PubMed
Arita H, Yamasaki K, Matsushita Y, A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 2016;4:79.27503138)| false
• Search Google Scholar
• Export Citation

Pekmezci M, Rice T, Molinaro AM, et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 2017;133:1001–1016.

• PubMed
Pekmezci M, Rice T, Molinaro AM, Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 2017;133:1001–1016.28255664)| false
• Search Google Scholar
• Export Citation

Möllemann M, Wolter M, Felsberg J, et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005;113:379–385.

• PubMed
Möllemann M, Wolter M, Felsberg J, Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005;113:379–385.15455350)| false
• Search Google Scholar
• Export Citation

Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003.

• PubMed
Hegi ME, Diserens AC, Gorlia T, MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003.15758010)| false
• Search Google Scholar
• Export Citation

Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871–1874.

• PubMed
Hegi ME, Diserens AC, Godard S, Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871–1874.15041700)| false
• Search Google Scholar
• Export Citation

Bell EH, Zhang P, Fisher BJ, et al. Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG Oncology/RTOG 0424 trial. JAMA Oncol 2018;4:1405–1409.

• PubMed
Bell EH, Zhang P, Fisher BJ, Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG Oncology/RTOG 0424 trial. JAMA Oncol 2018;4:1405–1409.29955793)| false
• Search Google Scholar
• Export Citation

Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012;13:916–926.

• PubMed
Malmström A, Grønberg BH, Marosi C, Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012;13:916–926.22877848)| false
• Search Google Scholar
• Export Citation

Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13:707–715.

• PubMed
Wick W, Platten M, Meisner C, Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13:707–715.22578793)| false
• Search Google Scholar
• Export Citation

Khuong-Quang DA, Buczkowicz P, Rakopoulos P, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 2012;124:439–447.

• PubMed
Khuong-Quang DA, Buczkowicz P, Rakopoulos P, K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 2012;124:439–447.22661320)| false
• Search Google Scholar
• Export Citation

Korshunov A, Capper D, Reuss D, et al. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 2016;131:137–146.

• PubMed
Korshunov A, Capper D, Reuss D, Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 2016;131:137–146.26482474)| false
• Search Google Scholar
• Export Citation

Horbinski C. To BRAF or not to BRAF: is that even a question anymore? J Neuropathol Exp Neurol 2013;72:2–7.

• PubMed
Horbinski C. To BRAF or not to BRAF: is that even a question anymore? J Neuropathol Exp Neurol 2013;72:2–7.23242278)| false
• Search Google Scholar
• Export Citation

Hawkins C, Walker E, Mohamed N, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 2011;17:4790–4798.

• PubMed
Hawkins C, Walker E, Mohamed N, BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 2011;17:4790–4798.21610142)| false
• Search Google Scholar
• Export Citation

Horbinski C, Nikiforova MN, Hagenkord JM, et al. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol 2012;14:777–789.

• PubMed
Horbinski C, Nikiforova MN, Hagenkord JM, Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol 2012;14:777–789.22492957)| false
• Search Google Scholar
• Export Citation

Penman CL, Faulkner C, Lowis SP, et al. Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomas. Front Oncol 2015;5:54.

• PubMed
Penman CL, Faulkner C, Lowis SP, Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomas. Front Oncol 2015;5:54.25785246)| false
• Search Google Scholar
• Export Citation

Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, et al. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 2013;37:685–698.

• PubMed
Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 2013;37:685–698.23552385)| false
• Search Google Scholar
• Export Citation

Horbinski C, Hamilton RL, Nikiforov Y, et al. Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 2010;119:641–649.

• PubMed
Horbinski C, Hamilton RL, Nikiforov Y, Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 2010;119:641–649.20044755)| false
• Search Google Scholar
• Export Citation

Mistry M, Zhukova N, Merico D, et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol 2015;33:1015–1022.

• PubMed
Mistry M, Zhukova N, Merico D, BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol 2015;33:1015–1022.25667294)| false
• Search Google Scholar
• Export Citation

Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–2516.

• PubMed
Chapman PB, Hauschild A, Robert C, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–2516.21639808)| false
• Search Google Scholar
• Export Citation

McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open- label study. Lancet Oncol 2014;15:323–332.

• PubMed
McArthur GA, Chapman PB, Robert C, Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open- label study. Lancet Oncol 2014;15:323–332.24508103)| false
• Search Google Scholar
• Export Citation

Kaley T, Touat M, Subbiah V, et al. BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET Study. J Clin Oncol 2018;36:3477–3484.

• PubMed
Kaley T, Touat M, Subbiah V, BRAF inhibition in BRAF^V600-mutant gliomas: results from the VE-BASKET Study. J Clin Oncol 2018;36:3477–3484.)| false
• Search Google Scholar
• Export Citation

Chang S, Zhang P, Cairncross JG, et al. Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. Neuro Oncol 2017;19:252–258.

• PubMed
Chang S, Zhang P, Cairncross JG, Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. Neuro Oncol 2017;19:252–258.27994066)| false
• Search Google Scholar
• Export Citation

Clark KH, Villano JL, Nikiforova MN, et al. 1p/19q testing has no significance in the workup of glioblastomas. Neuropathol Appl Neurobiol 2013;39:706–717.

• PubMed
Clark KH, Villano JL, Nikiforova MN, 1p/19q testing has no significance in the workup of glioblastomas. Neuropathol Appl Neurobiol 2013;39:706–717.23363074)| false
• Search Google Scholar
• Export Citation

Alnahhas I, Rayi A, Thomas D, et al. False-positive 1p/19q testing results in gliomas: clinical and research consequences. Am J Clin Oncol 2020;43:802–805.

• PubMed
Alnahhas I, Rayi A, Thomas D, False-positive 1p/19q testing results in gliomas: clinical and research consequences. Am J Clin Oncol 2020;43:802–805.32889892)| false
• Search Google Scholar
• Export Citation

Ball MK, Kollmeyer TM, Praska CE, et al. Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas. Neurooncol Adv 2020;2:vdaa109.

• PubMed
Ball MK, Kollmeyer TM, Praska CE, Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas. Neurooncol Adv 2020;2:vdaa109.33205043)| false
• Search Google Scholar
• Export Citation

Olar A, Wani KM, Alfaro-Munoz KD, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol 2015;129:585–596.

• PubMed
Olar A, Wani KM, Alfaro-Munoz KD, IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol 2015;129:585–596.25701198)| false
• Search Google Scholar
• Export Citation

Bechet D, Gielen GG, Korshunov A, et al. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol 2014;128:733–741.

• PubMed
Bechet D, Gielen GG, Korshunov A, Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol 2014;128:733–741.25200321)| false
• Search Google Scholar
• Export Citation

Hegi ME, Genbrugge E, Gorlia T, et al. MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: a pooled analysis of four clinical trials. Clin Cancer Res 2019;25:1809–1816.

• PubMed
Hegi ME, Genbrugge E, Gorlia T, MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: a pooled analysis of four clinical trials. Clin Cancer Res 2019;25:1809–1816.30514777)| false
• Search Google Scholar
• Export Citation

Vlassenbroeck I, Califice S, Diserens AC, et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10:332–337.

• PubMed
Vlassenbroeck I, Califice S, Diserens AC, Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10:332–337.18556773)| false
• Search Google Scholar
• Export Citation

Quillien V, Lavenu A, Karayan-Tapon L, et al. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118:4201–4211.

• PubMed
Quillien V, Lavenu A, Karayan-Tapon L, Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118:4201–4211.)| false
• Search Google Scholar
• Export Citation